Thermalytix: AI-Powered Breast Cancer Screening Test

What is Thermalytix 

Thermalytix is a Novel Artificial Intelligence based medical device for breast cancer screening test. It is an affordable, portable, safe and accurate method of detecting breast abnormalities. It is radiation free , employs no touch and no see approach and works for women of all age groups.

How does Thermalytix – Breast Cancer Screening Test work

The solution uses a high resolution thermal sensing device and a cloud hosted analytics solution for analyzing the thermal images for reliable, early and accurate breast cancer screening.Thermalytix employs innovative proprietary machine learning and deep learning algorithms to analyze temperature distribution on the chest, to automatically generate a quantitative report showing a breast health score and assist doctors in identifying abnormal breast lesion.

Benefits of Thermalytix

Non Contact Private Screening

The equipment is placed at 3ft from the patient. offering a no-touch, no-visual approach that ensures a painless procedure

No Side Effects

Thermalytix does not use radiation of any form & measures temperatures
on the body.

Portable Equipment

The thermal sensor used by Niramai can be carried to any location in an
ordinary backpack increasing accessibility of screening test

Low Cost Per Screening

Niramai technology cost per screening is significantly lower compared to
other modalities.

Early Detection

Detects tumors significantly smaller (5mm) than what can be detected
with physical examination (25mm).

Age Agnostic:

It is age and breast density agnostic and works even for women below 40
years for whom Mammography is not recommended

2,50,000+

Screenings Completed

10,000+

Screening Camps

160+

Locations in India

32+

Cities

8+

Countries

Regulatory Approved
FDA Cleared
CE Certified
ISO Logo
CDSCO

Clinically Proven
Clinically proven

35+

Multinational Patents

Global Reach and Quality Assurance

Thermalytix is commercially available in India, UAE, Kenya, Philippines, Sweden, Bulgaria and Turkey.Thermalytix has obtained a CE Mark for all European countries and regulatory clearance in the above countries.The innovative methods used in our test have led to 35+ granted patents

Niramai Quality Management Processes are certified to be compliant with ISO 13485 and MDSAP.  We follow good clinical practices, comply with information security and data privacy policies, as per EU GDPR and US HIPAA requirements.

Clinical Studies & Publications of Thermalytix

Results of multiple clinical studies comparing Thermalytix with current standard of care have been published in peer  reviewed conference/journals. The results from these clinical trials indicate very high accuracy of Thermalytix that is non-inferior to X-Ray Mammography in general, and 25%  better sensitivity than mammography in women with dense breasts.

Some clinical studies and real world evaluations published in top peer reviewed journal publications are listed below.

BMJ Open Journal

Multicentric study to evaluate the effectiveness of Thermalytix as compared with standard screening modalities in subjects who show possible symptoms of suspected breast cancer.

Read More

ASCO JCO Journal

Observational study on the clinical efficacy of Thermalytix for detecting breast cancer in symptomatic and asymptomatic women, published in the Journal of Clinical Oncology Global Oncology.

Read More

Frontiers in AI Journal

Prospective evaluation of breast thermography enhanced by a novel machine learning technique for screening breast abnormalities in women at a secondary care hospital, published in Frontiers.

Read More

International Journal Of Community Medicine

Feasibility and outcomes of using a novel artificial intelligence enhanced breast thermography technique, Thermalytix, in screening for breast abnormalities at primary health centres at the community level in South India

Read More

Lancet Oncology

Performance of artificial intelligence-based breast cancer screening in a community setting: a real-world evaluation study. The Lancet Oncology. 2022 Jul 1;23:S20

Read More

SABCS 2022

An Automated Risk Stratification System for Breast Cancer Screening using Thermalytix. Cancer Research. 2023 Mar 1;and San Antonio Breast Cancer Symposium Dec 2022:P3-03

Read More

You can access the full list of Peer-Reviewed Publications about Thermalytix Below:

Read More